drugset / Trial / NCT01425450

Safety Study of Four Doses of the Study Drug, HF1020 in Healthy Volunteers

NCT01425450 ↗

Phase 1 Completed 32 enrolled Trident Pharmaceuticals Inc
RandomizedSingle-groupDouble-blindTreatment

Summary

The study aims to: * study the safety of the drug (HF1020) in healthy male adults * study how well the study drug (HF1020) is tolerated in healthy male adults * find the maximum dose that is tolerated in healthy male adults

Timeline

Start
2011-07
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HF1020 Unknown 0.5 mg —
Subject HF1020 Unknown 2.5 mg —
Subject HF1020 Unknown 10 mg —
Subject HF1020 Unknown 25 mg —

Indications

No indication recorded.